| P2093 | author name string | Rolf M F Berger | |
| | Mark-Jan Ploegstra | |
| | Willemijn M H Zijlstra | |
| P2860 | cites work | Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry | Q46954401 |
| | Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? | Q46983727 |
| | Biventricular structural and functional responses to aortic constriction in a rabbit model of chronic right ventricular pressure overload | Q47361173 |
| | Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival | Q47578101 |
| | Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension | Q47865318 |
| | Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies | Q48137025 |
| | Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results. | Q48471209 |
| | Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. | Q48548676 |
| | Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension | Q48553623 |
| | Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial | Q48674231 |
| | The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension | Q48921974 |
| | Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension | Q49124631 |
| | Bosentan in pediatric patients with pulmonary arterial hypertension | Q50356493 |
| | An epidemiological study of pulmonary arterial hypertension. | Q50800629 |
| | Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. | Q51170378 |
| | Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. | Q51556854 |
| | Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. | Q51688048 |
| | Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years. | Q51755418 |
| | Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. | Q51764417 |
| | Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. | Q52422731 |
| | First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. | Q52931065 |
| | Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. | Q52956582 |
| | Utility of cardiopulmonary stress testing in assessing disease severity in children with pulmonary arterial hypertension. | Q53868649 |
| | Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. | Q54076009 |
| | Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. | Q54149023 |
| | Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. | Q54430921 |
| | Pulmonary Arterial Hypertension | Q56388760 |
| | Do Changes of 6-Minute Walk Distance Predict Clinical Events in Patients With Pulmonary Arterial Hypertension? | Q57618842 |
| | Circulating Endothelial Cells | Q57767355 |
| | Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension | Q57824012 |
| | Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue | Q57824424 |
| | Bosentan–sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology | Q58067354 |
| | Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells | Q21133932 |
| | Treatment goals of pulmonary hypertension | Q26851767 |
| | Pulmonary arterial hypertension: a comparison between children and adults | Q27687320 |
| | Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial | Q28374317 |
| | Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the Magic registry | Q30429733 |
| | Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. | Q33147483 |
| | Inhaled iloprost for severe pulmonary hypertension | Q33147955 |
| | Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension | Q33153278 |
| | Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension | Q33154973 |
| | Atrial septostomy improves survival in select patients with pulmonary hypertension. | Q33155048 |
| | Heart rate variability predicts outcome in children with pulmonary arterial hypertension | Q33157058 |
| | Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. | Q33157493 |
| | Childhood idiopathic pulmonary arterial hypertension: a national cohort study | Q33158662 |
| | Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management | Q33160682 |
| | Clinical features of paediatric pulmonary hypertension: a registry study | Q33160860 |
| | Initial experience with tadalafil in pediatric pulmonary arterial hypertension | Q33161066 |
| | Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. | Q33161210 |
| | Riociguat for the treatment of pulmonary arterial hypertension | Q33163083 |
| | Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension | Q33173560 |
| | Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. | Q33588179 |
| | Pulmonary arterial hypertension in France: results from a national registry | Q33993302 |
| | Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. | Q34035546 |
| | PDGF signaling in pulmonary arterial hypertension | Q34048526 |
| | Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy | Q34088723 |
| | Long-Term Outcomes in Children With Pulmonary Arterial Hypertension Treated With Bosentan in Real-World Clinical Settings | Q34254924 |
| | Survival with first-line bosentan in patients with primary pulmonary hypertension. | Q34389894 |
| | Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. | Q34402406 |
| | Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. | Q34424315 |
| | Usefulness of right-to-left shunting and poor exercise gas exchange for predicting prognosis in patients with pulmonary arterial hypertension | Q34541810 |
| | Sildenafil citrate therapy for pulmonary arterial hypertension | Q34562650 |
| | Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In | Q34999923 |
| | Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial | Q44240810 |
| | Macitentan and morbidity and mortality in pulmonary arterial hypertension | Q44343572 |
| | Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension | Q44413117 |
| | Bilateral lung transplantation for pediatric idiopathic pulmonary arterial hypertension: a multi-center experience | Q44426914 |
| | Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria | Q44443489 |
| | Beraprost therapy for pulmonary arterial hypertension | Q44487843 |
| | Vasodilator therapy for primary pulmonary hypertension in children | Q44517314 |
| | A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension | Q44938984 |
| | Outcomes in children with idiopathic pulmonary arterial hypertension. | Q45004050 |
| | Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension | Q45168833 |
| | Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension | Q45251155 |
| | Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. | Q45907174 |
| | Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. | Q45956408 |
| | Tadalafil therapy for pulmonary arterial hypertension. | Q45995795 |
| | Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension | Q46047753 |
| | Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. | Q46295017 |
| | Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children | Q46391899 |
| | Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial | Q46418787 |
| | Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study | Q46547011 |
| | Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. | Q46573264 |
| | Usefulness of the right ventricular systolic to diastolic duration ratio to predict functional capacity and survival in children with pulmonary arterial hypertension | Q46624826 |
| | Ambrisentan therapy for pulmonary arterial hypertension | Q46626290 |
| | Effects of long-term bosentan in children with pulmonary arterial hypertension. | Q46648621 |
| | Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan | Q46651611 |
| | Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study | Q46694356 |
| | Biological serum markers in the management of pediatric pulmonary arterial hypertension | Q46743475 |
| | Goal-oriented treatment and combination therapy for pulmonary arterial hypertension | Q46786766 |
| | Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children | Q46927431 |
| | Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension | Q35076114 |
| | Functional classification of pulmonary hypertension in children: Report from the PVRI pediatric taskforce, Panama 2011. | Q35180290 |
| | Surrogate endpoints: a basis for a rational approach | Q35488355 |
| | The endothelin system in pulmonary arterial hypertension | Q35635106 |
| | Response to bosentan in children with pulmonary hypertension | Q35771679 |
| | Cellular and molecular pathobiology of pulmonary arterial hypertension | Q35803229 |
| | Treatment of pulmonary arterial hypertension | Q35905944 |
| | Perioperative complications in children with pulmonary hypertension undergoing noncardiac surgery or cardiac catheterization | Q35916967 |
| | B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. | Q35968889 |
| | Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. | Q36427718 |
| | Biomarkers and surrogate endpoints in clinical trials | Q36552129 |
| | Molecular pathogenesis of pulmonary arterial hypertension | Q36736065 |
| | Percutaneous balloon dilatation of the atrial septum: immediate and midterm results | Q36838712 |
| | Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy | Q37192330 |
| | Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension | Q37274564 |
| | How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension? | Q37799653 |
| | Treatment options for paediatric pulmonary arterial hypertension | Q37813918 |
| | Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension | Q37872433 |
| | Lung transplantation in children with idiopathic pulmonary arterial hypertension: an 18-year experience | Q37881159 |
| | Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. | Q38065713 |
| | Pediatric pulmonary hypertension. | Q38172723 |
| | Updated treatment algorithm of pulmonary arterial hypertension. | Q38172728 |
| | Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). | Q38372331 |
| | STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension | Q38434262 |
| | Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial | Q38457832 |
| | A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension | Q38480301 |
| | Comparison of 6-min walk test distance and cardiopulmonary exercise test performance in children with pulmonary hypertension | Q39829787 |
| | Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study | Q42654610 |
| | Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial | Q43079774 |
| | Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial | Q43214941 |
| | Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension | Q43243364 |
| | Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program | Q43527880 |
| | Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre | Q43680261 |
| | Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial | Q43977511 |
| | Tricuspid annular displacement predicts survival in pulmonary hypertension | Q44026625 |
| | Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. | Q44120529 |
| | Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension | Q44126114 |
| | Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. | Q44138534 |
| | The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Pediatric Lung and Heart-Lung Transplantation Report--2013; focus theme: age. | Q44175021 |
| P433 | issue | 5 | |
| P921 | main subject | arterial hypertension | Q41861 |
| P304 | page(s) | 615-628 | |
| P577 | publication date | 2014-07-22 | |
| P1433 | published in | Expert Review of Respiratory Medicine | Q15754583 |
| P1476 | title | Current and advancing treatments for pulmonary arterial hypertension in childhood | |
| P478 | volume | 8 | |